| Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention DT Michaeli, JC Michaeli, S Albers, T Boch, T Michaeli American Journal of Cardiovascular Drugs 23 (5), 477-495, 2023 | 25 | 2023 |
| Medical education and mental health during COVID-19: a survey across 9 countries D Michaeli, G Keough, F Perez-Dominguez, F Polanco-Ilabaca, ... International journal of medical education 13, 35, 2022 | 24 | 2022 |
| Socio-economic burden of disease: Survivorship costs for bladder cancer JC Michaeli, T Boch, S Albers, T Michaeli, DT Michaeli Journal of Cancer Policy 32, 100326, 2022 | 16 | 2022 |
| Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy DT Michaeli, T Michaeli, S Albers, T Boch, JC Michaeli The European Journal of Health Economics, 1-19, 2023 | 13 | 2023 |
| Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany DT Michaeli, JC Michaeli, T Boch, T Michaeli Cardiovascular drugs and therapy 37 (4), 683-694, 2023 | 9 | 2023 |
| Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with statins compared to statin monotherapy DT Michaeli, JC Michaeli, T Boch, T Michaeli Clinical Drug Investigation 42 (8), 643-656, 2022 | 8 | 2022 |
| Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa DT Michaeli, S Stoycheva, SM Marcus, W Zhang, JC Michaeli, T Michaeli Clinical Drug Investigation 42 (4), 333-343, 2022 | 8 | 2022 |
| Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations DT Michaeli, T Michaeli, S Albers, JC Michaeli JNCI: Journal of the National Cancer Institute 116 (2), 216-229, 2024 | 7 | 2024 |
| The healthcare labor shortage: Practice, theory, evidence, and ways forward DT Michaeli, JC Michaeli, S Albers, T Michaeli Theory, Evidence, and Ways Forward (March 26, 2022), 2022 | 5 | 2022 |
| Advances in cancer therapy: clinical benefit of new cancer drugs DT Michaeli, JC Michaeli, T Michaeli Aging (Albany NY) 15 (12), 5232, 2023 | 4 | 2023 |
| Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab DT Michaeli, JC Michaeli, T Boch, T Michaeli European Heart Journal 43 (Supplement_2), ehac544. 2367, 2022 | 4 | 2022 |
| Association between clinical trial design characteristics and treatment effect estimates: A meta-analysis of randomized-controlled and single-arm trials supporting the FDA … DT Michaeli, T Michaeli, S Albers, JC Michaeli Available at SSRN 4546126, 2023 | 3 | 2023 |
| Testicular cancer follow-up costs in Germany from 2000 to 2015 T Michaeli, J Michaeli, D Michaeli Journal of Cancer Research and Clinical Oncology 147, 2249-2258, 2021 | 3 | 2021 |
| Concurrent stimulation of monocytes with CSF1 and polarizing cytokines reveals phenotypic and functional differences with classical polarized macrophages L An, J Michaeli, P Pallavi, A Breedijk, X Xu, N Dietrich, M Sigl, M Keese, ... Journal of Leukocyte Biology 112 (3), 437-447, 2022 | 2 | 2022 |
| Socio‐economic burden of disease: survivorship costs for renal cell carcinoma JC Michaeli, DT Michaeli, T Boch, S Albers, T Michaeli European Journal of Cancer Care 31 (3), e13569, 2022 | 1 | 2022 |
| Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications DT Michaeli, T Michaeli, S Albers, JC Michaeli BMJ Evidence-Based Medicine, 2024 | | 2024 |
| 238P Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovativeness, trials, endpoints, and price JC Michaeli, CT Michaeli, D Trapani, S Albers, D Dannehl, R Würstlein, ... ESMO Open 9, 2024 | | 2024 |
| 1697MO Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases JC Michaeli, CT Michaeli, DT Michaeli Annals of Oncology 34, S927-S928, 2023 | | 2023 |
| Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells JC Michaeli, S Albers, C de la Torre, Y Schreiner, S Faust, T Michaeli, ... Scientific Reports 13 (1), 16159, 2023 | | 2023 |
| Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs DT Michaeli, T Michaeli, S Albers, JC Michaeli Available at SSRN 4539257, 2023 | | 2023 |
Daniel Tobias MichaeliHeidelberg UniversityVerified email at stud.uni-heidelberg.de
Daniel Tobias MichaeliHeidelberg UniversityVerified email at stud.uni-heidelberg.de